DARE - Dare? Bioscience Highlights Efficacy Data From Treatment Candidate For Painful Menstruation | Benzinga
Daré Bioscience Inc (NASDAQ: DARE) announced topline results from the Phase 1 DARE-PDM1-001 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1 an investigational product designed to deliver diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), vaginally via its proprietary hydrogel for primary dysmenorrhea.
Dysmenorrhea is defined as painful menstruation in women with normal pelvic anatomy.
The Phase 1 study results indicate that the study treatment was well-tolerated, and treatment-emergent adverse events profiles were comparable between ...